In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature program, an innovative approach ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

*AA Signature, by Allergan Aesthetics, is a new program that is launching Internationally at the IMCAS congress in Paris and will be considered for roll out across International markets, as ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

NORTH CHICAGO, Ill., Jan. 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, continues to innovate and elevate the patient journey with ...

AbbVie cautions that these forward-looking statements are subject ... To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.

AbbVie is still carrying over $71 billion in long-term debt from an acquisition spree that included a $63 billion purchase of Allergan, $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's ...

NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a global biopharmaceutical company with a market capitalization of $299 billion and annual revenue exceeding $55 billion, has announced the completion ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most ...